LTX 109

Drug Profile

LTX 109

Alternative Names: LTX-109; Lytixar

Latest Information Update: 07 Sep 2015

Price : $50

At a glance

  • Originator Lytix Biopharma
  • Class Antibacterials; Oligopeptides; Small molecules
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Impetigo
  • Preclinical Diabetic foot ulcer
  • No development reported Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections

Most Recent Events

  • 07 Sep 2015 No recent reports on development identified - Phase-I/II for Methicillin-resistant Staphylococcus aureus infections in Sweden (Topical)
  • 07 Sep 2015 No recent reports on development identified - Phase-II for Skin and soft tissue infections in Hungary (Topical)
  • 07 Sep 2015 Preclinical trials in Diabetic foot ulcer in Norway (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top